论文部分内容阅读
目的探讨巴曲酶与依达拉奉联合治疗进展性脑梗死的疗效和安全性。方法选取68例进展性脑梗死患者,并随机分成治疗组(巴曲酶+依达拉奉)36例和对照组(依达拉奉)32例,观察2组治疗前后血液流变学指标、血清神经元特异性烯醇化酶(NSE)、美国国立卫生研究院卒中量表(NI HSS)和日常生活活动能力量表(BI)评分的变化,并比较出血率及肝、肾功能损害的发生率。结果治疗组治疗后多项血液流变学指标均有明显降低(P均<0.01)。2组治疗后NSE较治疗前均有明显下降(P均<0.01)。2组治疗后NI H-SS评分、BI评分比较显示治疗组较对照组的神经功能恢复得更好(P<0.05)。2组出血发生率比较差异无显著性(P>0.05)。所有病例无严重不良反应发生。结论巴曲酶联合依达拉奉治疗进展性脑梗死安全、有效。
Objective To investigate the efficacy and safety of batroxobin and edaravone in the treatment of advanced cerebral infarction. Methods Sixty-eight patients with progressive cerebral infarction were randomly divided into treatment group (Batroxobin and Edaravone) 36 cases and control group (Edaravone) 32 cases. The indexes of hemorheology before and after treatment were observed, Serum neuron-specific enolase (NSE), NIH Stroke Scale (NIHSS) and daily living activity scale (BI) scores were compared and the incidence of bleeding and the occurrence of liver and kidney dysfunction were compared rate. Results After treatment, the number of hemorheological indexes in the treatment group decreased significantly (all P <0.01). The NSE in both groups decreased significantly after treatment (P <0.01). NI H-SS score and BI score after treatment showed that the neurological function recovery of the treatment group was better than that of the control group (P <0.05). There was no significant difference in the incidence of bleeding between the two groups (P> 0.05). No serious adverse reactions occurred in all cases. Conclusions Batroxobin and edaravone are safe and effective in treating progressive cerebral infarction.